Amendments To The Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

In the Claims:

What is claimed is:

1. (Original) A compound of Formula (I):



(I)

or a salt, solvate, or physiologically functional derivative thereof;
wherein:

D_1 is aryl, heteroaryl, or heterocyclic said aryl, heteroaryl and heterocyclic groups being optionally substituted with at least one group R;

R is independently selected from the group consisting of halo, C_1-C_6 alkyl, C_2-C_6 alkynyl, C_1-C_6 alkoxy, $-NR^1R^2$, C_1-C_4 haloalkyl, hydroxy, $-C(O)R^1$, $-OC(O)R^1$, $-C(O)NR^1R^2$, $-S(O)_2R^1$, C_1-C_6 alkylsulfanyl, cyano, C_1-C_2 halalkoxy, or

the group defined by $-(Y)_o-(Y^1)_r-(Y^2)$;

wherein:

Y is O and o is 0 or 1;

Y^1 is C(H)(R'), and r is 0, 1, 2, 3, or 4; and

Y^2 is aryl, heteroaryl, heterocyclic, C_3-C_7 cycloalkly, or C_2-C_6 alkenyl;

D_2 is hydrogen or C_1-C_4 alkyl;

D_3 is aryl or heteroaryl said aryl or heteroaryl groups being optionally substituted with at least one group Q;

Q is independently selected from the group consisting of halo, C_1-C_4 haloalkyl, C_1-C_6 alkyl, C_1-C_6 alkoxy, C_1-C_4 haloalkoxy, hydroxy, aralkoxy, C_1-C_6 alkenyl, alkynyl, C_1-C_4 hydroxyalkyl, cyano, aryloxy, C_1-C_2 halalkoxy, $-NO_2$, or $-C(O)OR^1$, or

the group defined by $-(Z)_q-(Z^1)_r-(Z^2)$,

wherein:

Z is NH and q is 0 or 1; or

Z is CH_2 and q is 0, 1, 2, or 3; or

Z is $O(CH_2)_n$, where n is 1, 2, 3, or 4 and q is 0 or 1;

Z^1 is $S(O)_2$ or C(O); and r is 0 or 1, and

Z^2 is C_1-C_6 alkyl, aryl, heteroaryl, heterocyclic, hydroxy, halo, aralkyl, C_1-C_2 haloalkyl, $C(H)(R')R^3$, $NH(CH_2)_nNR^1R^2$, $NH(CH_2)_nR^3$, $NH(CH_2)_nOR^1$ or NR^1R^2 where n is 1, 2, 3, or 4 ;

R^1 is hydrogen, C_1-C_4 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, aryl, heteroaryl, C_3-C_7 cycloalkyl, heterocyclic, or aralkyl;

R^2 is hydrogen, C_1-C_4 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, aryl, heteroaryl, C_3-C_7 cycloalkyl, heterocyclic, or aralkyl;

R^3 is heteroaryl or heterocyclic, and

R' is hydrogen or C_1-C_3 alkyl.

2. (Original) A compound of Formula (I):



(I)

or a salt, solvate, or physiologically functional derivative thereof;

wherein:

D_1 is





where

X is selected from N, O, or S;

X_a is N and X_b is N, O, or S, or

X_a is O and X_b is N, or

X_a is S and X_b is N;

m is 0, 1, 2, 3, or 4;

R is independently selected from the group consisting of halo, C_1-C_6 alkyl, C_2-C_6 alkynyl, C_1-C_6 alkoxy, -NR^1R^2, C_1-C_4 haloalkyl, hydroxy, -$C(O)R^1$, -$OC(O)R^1$, -$C(O)NR^1R^2$, -$S(O)_2R^1$, C_1-C_6 alkylsulfanyl, cyano, C_1-C_2 halalkoxy, or

the group defined by -$(Y)_o$-$(Y^1)_r$-(Y^2);

wherein:

Y is O and o is 0 or 1;

Y^1 is C(H)(R'), and r is 0, 1, 2, 3, or 4; and

Y^2 is aryl, heteroaryl, heterocyclic, C_3-C_7 cycloalkyl, or C_2-C_6 alkenyl;

D_2 is hydrogen or C_1-C_4 alkyl;

D_3 is selected from the group



where X is selected from N, O, or S, and

p is 0, 1, 2, 3, 4, or 5;

Q is independently selected from the group consisting of halo, C_1-C_4 haloalkyl, C_1-C_6 alkyl, C_1-C_6 alkoxy, C_1-C_4 haloalkoxy, hydroxy, aralkoxy, C_1-C_6 alkenyl, alkynyl, C_1-C_4 hydroxyalkyl, cyano, aryloxy, C_1-C_2 halalkoxy, $-NO_2$, or $-C(O)OR^1$, or

the group defined by $-(Z)_q-(Z^1)_r-(Z^2)$,

wherein:

Z is NH and q is 0 or 1; or

Z is CH_2 and q is 0, 1, 2, or 3; or

Z is $O(CH_2)_n$ where n is 1, 2, 3, or 4 and q is 0 or 1;

Z^1 is $S(O)_2$ or C(O); and r is 0 or 1, and

Z^2 is C_1-C_6 alkyl, aryl, heteroaryl, heterocyclic, hydroxy, halo, aralkyl, C_1-C_2 haloalkyl, $C(H)(R')R^3$, $NH(CH_2)_nNR^1R^2$, $NH(CH_2)_nR^3$, $NH(CH_2)_nOR^1$ or NR^1R^2; where n is 1, 2, 3, or 4;

R^1 is hydrogen, C_1-C_4 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, aryl, heteroaryl, C_3-C_7 cycloalkyl, heterocyclic, or aralkyl;

R^2 is hydrogen, C_1-C_4 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, aryl, heteroaryl, C_3-C_7 cycloalkyl, heterocyclic, or aralkyl;

R^3 is heteroaryl or heterocyclic, and

R' is hydrogen or C_1-C_3 alkyl.

3. (Original) A compound of Formula (II):



(II)

or a salt, solvate, or physiologically functional derivative thereof;

wherein:

m is 0, 1, 2, 3, or 4;

p is 0, 1, 2, 3, 4, or 5;

R is independently selected from the group consisting of halo, C_1-C_6 alkyl, C_2-C_6 alkynyl, C_1-C_6 alkoxy, -NR^1R^2, C_1-C_4 haloalkyl, hydroxy, -$C(O)R^1$, -$OC(O)R^1$, -$C(O)NR^1R^2$, -$S(O)_2R^1$, C_1-C_6 alkylsulfanyl, cyano, C_1-C_2 halalkoxy, or

the group defined by -$(Y)_o$-$(Y^1)_r$-(Y^2);

wherein:

Y is O and o is 0 or 1;

Y^1 is C(H)(R'), and r is 0, 1, 2, 3, or 4; and

Y^2 is aryl, heteroaryl, heterocyclic, C_3-C_7 cycloalkyl, or C_2-C_6 alkenyl;

Q is independently selected from the group consisting of halo, C_1-C_4 haloalkyl, C_1-C_6 alkyl, C_1-C_6 alkoxy, C_1-C_4 haloalkoxy, hydroxy, aralkoxy, C_1-C_6 alkenyl, alkynyl, C_1-C_4 hydroxyalkyl, cyano, aryloxy, C_1-C_2 halalkoxy, -NO_2, or -$C(O)OR^1$, or

the group defined by -$(Z)_q$-$(Z^1)_r$-(Z^2),

wherein:

Z is NH and q is 0 or 1; or

Z is CH_2 and q is 0, 1, 2, or 3; or

Z is $O(CH_2)_n$ where n is 1, 2, 3, or 4 and q is 0 or 1;

Z^1 is $S(O)_2$ or C(O); and r is 0 or 1, and

Z^2 is C_1-C_6 alkyl, aryl, heteroaryl, heterocyclic, hydroxy, halo, aralkyl, C_1-C_2 haloalkyl, $C(H)(R')R^3$, $NH(CH_2)_nNR^1R^2$, $NH(CH_2)_nR^3$, $NH(CH_2)_nOR^1$ or NR^1R^2, where n is 1, 2, 3, or 4;

R^1 is hydrogen, C_1-C_4 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, aryl, heteroaryl, C_3-C_7 cycloalkyl, heterocyclic, or aralkyl;
R^2 is hydrogen, C_1-C_4 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, aryl, heteroaryl, C_3-C_7 cycloalkyl, heterocyclic, or aralkyl;
R^3 is heteroaryl or heterocyclic, and
R' is hydrogen or C_1-C_3 alkyl.

4. (Original) A compound of Formula (III):



(III)

or a salt, solvate, or physiologically functional derivative thereof;
wherein:
R is independently selected from the group consisting of C_1-C_6 alkoxy, hydroxy, C_1-C_6 alkylsulfanyl, C_1-C_2 haloalkoxy, or
the group defined by $-(Y)_o-(Y^1)_r-(Y^2)$;
wherein:
Y is O and o is 0 or 1;
Y^1 is C(H)(R'), and r is 0, 1, 2, 3, or 4; and
Y^2 is aryl, heteroaryl, heterocyclic, or C_3-C_7 cycloalkyl;

Q_2 is hydrogen, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, halo, cyano, or C_1-C_4 haloalkyl;

Q_3 is hydrogen or

the group defined by $-(Z)_q-(Z^1)_r-(Z^2)$,

wherein:

Z is CH_2 and q is 0, 1, or 2; or

Z is $O(CH_2)_n$ where n is 1, 2, 3, or 4 and q is 0 or 1;

Z^1 is C(O); and r is 0 or 1, and

Z^2 is $NH(CH_2)_nNR^1R^2$ or NR^1R^2, where n is 1, 2, 3, or 4;

R^1 is hydrogen, C_1-C_4 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, aryl, heteroaryl, C_3-C_7 cycloalkyl, heterocyclic, or aralkyl;

R^2 is hydrogen, C_1-C_4 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, aryl, heteroaryl, C_3-C_7 cycloalkyl, heterocyclic, or aralkyl;

R^3 is heteroaryl or heterocyclic;

R' is hydrogen or C_1-C_3 alkyl; and

X is CH or N.

5. (Original) A compound as claimed in claim 1, selected from the group consisting of:

5-(3-methoxyphenyl)-*N*-phenyl-1,3-oxazol-2-amine;

3-(2-anilino-1,3-oxazol-5-yl)phenol;

N-[4-(4-methylpiperazin-1-yl)phenyl]-5-phenyl-1,3-oxazol-2-amine;

5-(3-methoxyphenyl)-*N*-[4-(4-methylpiperazin-1-yl)phenyl]-1,3-oxazol-2-amine;

N-[4-(4-ethylpiperazin-1-yl)phenyl]-5-(3-methoxyphenyl)-1,3-oxazol-2-amine;

N-[4-(4-ethylpiperazin-1-yl)phenyl]-5-phenyl-1,3-oxazol-2-amine;

N-[4-(morpholin-4-ylmethyl)phenyl]-5-phenyl-1,3-oxazol-2-amine;

5-(3-methoxyphenyl)-*N*-(4-morpholin-4-ylphenyl)-1,3-oxazol-2-amine;

5-(3-methoxyphenyl)-*N*-(4-piperidin-1-ylphenyl)-1,3-oxazol-2-amine;

5-(3-methoxyphenyl)-*N*-[4-(morpholin-4-ylmethyl)phenyl]-1,3-oxazol-2-amine;

5-(3-ethoxyphenyl)-*N*-[4-(4-methylpiperazin-1-yl)phenyl]-1,3-oxazol-2-amine;

5-(3-isopropoxyphenyl)-*N*-[4-(4-methylpiperazin-1-yl)phenyl]-1,3-oxazol-2-amine;

5-[3-(cyclopentyloxy)phenyl]-*N*-[4-(4-methylpiperazin-1-yl)phenyl]-1,3-oxazol-2-amine;

5-(3-isobutoxyphenyl)-*N*-[4-(4-methylpiperazin-1-yl)phenyl]-1,3-oxazol-2-amine;

5-[3-(benzyloxy)phenyl]-*N*-[4-(4-methylpiperazin-1-yl)phenyl]-1,3-oxazol-2-amine;

N-[4-(4-methylpiperazin-1-yl)phenyl]-5-{3-[(2-methylprop-2-enyl)oxy]phenyl}-1,3-oxazol-2-amine;

N-[4-(4-methylpiperazin-1-yl)phenyl]-5-(3-propoxyphenyl)-1,3-oxazol-2-amine;

5-[3-(cyclohexyloxy)phenyl]-*N*-[4-(4-methylpiperazin-1-yl)phenyl]-1,3-oxazol-2-amine;

N-[3-chloro-4-(4-methylpiperazin-1-yl)phenyl]-5-(3-methoxyphenyl)-1,3-oxazol-2-amine;

N-[3-fluoro-4-(4-methylpiperazin-1-yl)phenyl]-5-(3-methoxyphenyl)-1,3-oxazol-2-amine;

5-(3-methoxyphenyl)-*N*-[4-(4-methylpiperazin-1-yl)-3-(trifluoromethyl)phenyl]-1,3-oxazol-2-amine;

5-(3-methoxyphenyl)-*N*-[3-methyl-4-(4-methylpiperazin-1-yl)phenyl]-1,3-oxazol-2-amine;

N-[4-(3,5-dimethylpiperazin-1-yl)phenyl]-5-(3-methoxyphenyl)-1,3-oxazol-2-amine;

5-(3-methoxyphenyl)-*N*-[2-methyl-4-(4-methylpiperazin-1-yl)phenyl]-1,3-oxazol-2-amine;

5-[3-(cyclopentyloxy)phenyl]-*N*-[4-(4-methylpiperazin-1-yl)-3-(trifluoromethyl)phenyl]-1,3-oxazol-2-amine;

N-[3-chloro-4-(4-methylpiperazin-1-yl)phenyl]-5-[3-(cyclopentyloxy)phenyl]-1,3-oxazol-2-amine;

5-[3-(cyclopentyloxy)phenyl]-*N*-[3-methyl-4-(4-methylpiperazin-1-yl)phenyl]-1,3-oxazol-2-amine;

5-[3-(cyclopentyloxy)phenyl]-*N*-[3-fluoro-4-(4-methylpiperazin-1-yl)phenyl]-1,3-oxazol-2-amine;

3-(2-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-1,3-oxazol-5-yl)phenol;

5-[3-(cyclopentyloxy)phenyl]-*N*-(4-thiomorpholin-4-ylphenyl)-1,3-oxazol-2-amine;

N-[5-(3-methoxyphenyl)-1,3-oxazol-2-yl]-6-(4-methylpiperazin-1-yl)pyridin-3-amine;

6-(1*H*-imidazol-1-yl)-*N*-[5-(3-methoxyphenyl)-1,3-oxazol-2-yl]pyridin-3-amine;

N-[5-(3-methoxyphenyl)-1,3-oxazol-2-yl]-6-piperidin-1-ylpyridin-3-amine;

N-{5-[3-(cyclopentyloxy)phenyl]-1,3-oxazol-2-yl}-6-(4-methylpiperazin-1-yl)pyridin-3-amine;

N^2,N^2-diethyl-N^5-[5-(3-methoxyphenyl)-1,3-oxazol-2-yl]pyridine-2,5-diamine;

N^5-{5-[3-(cyclopentyloxy)phenyl]-1,3-oxazol-2-yl}-N^2,N^2-diethylpyridine-2,5-diamine;

N-{5-[3-(cyclopentyloxy)phenyl]-1,3-oxazol-2-yl}-5-methyl-6-(4-methylpiperazin-1-yl)pyridin-3-amine;

5-(3-methoxyphenyl)-*N*-{4-[(4-methylpiperazin-1-yl)methyl]phenyl}-1,3-oxazol-2-amine;

N-{4-[(4-methylpiperazin-1-yl)methyl]phenyl}-5-phenyl-1,3-oxazol-2-amine;

N-{4-[(dimethylamino)methyl]phenyl}-5-(3-methoxyphenyl)-1,3-oxazol-2-amine;

5-[3-(cyclopentyloxy)phenyl]-*N*-{4-[(dimethylamino)methyl]phenyl}-1,3-oxazol-2-amine;

N-{4-[2-(dimethylamino)ethyl]phenyl}-5-(3-methoxyphenyl)-1,3-oxazol-2-amine;

5-(3-methoxyphenyl)-*N*-[4-(piperidin-1-ylmethyl)phenyl]-1,3-oxazol-2-amine;

5-(3-methoxyphenyl)-*N*-[4-(pyrrolidin-1-ylmethyl)phenyl]-1,3-oxazol-2-amine;

N-{4-[(diethylamino)methyl]phenyl}-5-(3-methoxyphenyl)-1,3-oxazol-2-amine;

N-[2-(diethylamino)ethyl]-4-{[5-(3-methoxyphenyl)-1,3-oxazol-2-yl]amino}benzamide;

5-(3-methoxyphenyl)-*N*-{4-[(4-methylpiperazin-1-yl)carbonyl]phenyl}-1,3-oxazol-2-amine;

4-({5-[3-(cyclopentyloxy)phenyl]-1,3-oxazol-2-yl}amino)-*N*-[2-(diethylamino)ethyl]benzamide;

5-(3-methoxyphenyl)-*N*-[4-(1-propylpiperidin-4-yl)-1,3-thiazol-2-yl]-1,3-oxazol-2-amine;

N,5-diphenyl-1,3-oxazol-2-amine;

N-methyl-1-{4-[(5-phenyl-1,3-oxazol-2-yl)amino]phenyl}methanesulfonamide;

N-{4-[(methylsulfonyl)methyl]phenyl}-5-phenyl-1,3-oxazol-2-amine;

N,*N*-diethyl-4-methoxy-3-[(5-phenyl-1,3-oxazol-2-yl)amino]benzenesulfonamide;

N-butyl-4-methoxy-3-[(5-phenyl-1,3-oxazol-2-yl)amino]benzenesulfonamide;

N-(3,4-dimethoxyphenyl)-5-phenyl-1,3-oxazol-2-amine;

N-[5-(ethylsulfonyl)-2-methoxyphenyl]-5-phenyl-1,3-oxazol-2-amine;

5-phenyl-*N*-[3-(phenylsulfonyl)phenyl]-1,3-oxazol-2-amine;

N,*N*-diethyl-4-[(5-phenyl-1,3-oxazol-2-yl)amino]benzamide;

4-(ethylsulfonyl)-2-[(5-phenyl-1,3-oxazol-2-yl)amino]phenol;

N-(2-methoxyphenyl)-5-phenyl-1,3-oxazol-2-amine;

N-butyl-3-[(5-phenyl-1,3-oxazol-2-yl)amino]benzenesulfonamide;

N,*N*-dimethyl-4-[(5-phenyl-1,3-oxazol-2-yl)amino]benzenesulfonamide;

2,5-dimethoxy-4-[(5-phenyl-1,3-oxazol-2-yl)amino]benzenesulfonamide;

N-(2-methoxy-5-nitrophenyl)-5-phenyl-1,3-oxazol-2-amine;

2-{4-[(5-phenyl-1,3-oxazol-2-yl)amino]phenyl}ethanol;

1-{4-methoxy-3-[(5-phenyl-1,3-oxazol-2-yl)amino]phenyl}ethanone;

{3-[(5-phenyl-1,3-oxazol-2-yl)amino]phenyl}methanol;

N-[5-(ethylsulfonyl)-2-methoxyphenyl]-5-(3-methoxyphenyl)-1,3-oxazol-2-amine;

4-(2-{[5-(ethylsulfonyl)-2-methoxyphenyl]amino}-1,3-oxazol-5-yl)phenol;

3-{[5-(4-fluorophenyl)-1,3-oxazol-2-yl]amino}-4-methoxy-*N*,*N*-dimethylbenzenesulfonamide;

N-{5-(ethylsulfonyl)-2-[2-(1*H*-imidazol-1-yl)ethoxy]phenyl}-5-(4-fluorophenyl)-1,3-oxazol-2-amine;

N-[5-(ethylsulfonyl)-2-(2-pyridin-2-ylethoxy)phenyl]-5-phenyl-1,3-oxazol-2-amine;

N-{5-(ethylsulfonyl)-2-[2-(1*H*-1,2,3-triazol-1-yl)ethoxy]phenyl}-5-phenyl-1,3-oxazol-2-amine;

5-phenyl-*N*-(3,4,5-trimethoxyphenyl)-1,3-oxazol-2-amine;

N-(2,5-dimethoxyphenyl)-5-phenyl-1,3-oxazol-2-amine;

3-methyl-5-[(5-phenyl-1,3-oxazol-2-yl)amino]benzene-1,2-diol;

N-(3,5-dimethoxyphenyl)-5-phenyl-1,3-oxazol-2-amine;

N-(3-methylphenyl)-5-phenyl-1,3-oxazol-2-amine;

N-{3-[2-(1*H*-imidazol-1-yl)ethoxy]-4-methoxyphenyl}-5-phenyl-1,3-oxazol-2-amine;

N-{4-[2-(1*H*-imidazol-1-yl)ethoxy]-3-methoxyphenyl}-5-phenyl-1,3-oxazol-2-amine;

N-[5-(ethylsulfonyl)-2-methoxyphenyl]-5-(4-fluorophenyl)-1,3-oxazol-2-amine;

5-(4-fluorophenyl)-*N*-{2-methoxy-5-[(methylsulfonyl)methyl]phenyl}-1,3-oxazol-2-amine;

N-(5-{[5-(3-iodophenyl)-1,3-oxazol-2-yl]amino}-2-methylphenyl)methanesulfonamide;

3-{[5-(4-fluorophenyl)-1,3-oxazol-2-yl]amino}-*N*,*N*-dimethylbenzenesulfonamide;

N-[3-(ethylsulfonyl)phenyl]-5-(4-fluorophenyl)-1,3-oxazol-2-amine;

3-{[5-(4-fluorophenyl)-1,3-oxazol-2-yl]amino}-4-methoxy-*N*-(pyridin-2-ylmethyl)benzenesulfonamide;

5-(4-fluorophenyl)-*N*-[2-methoxy-5-(methylsulfonyl)phenyl]-1,3-oxazol-2-amine;

N-{2-methoxy-5-[(2-pyridin-2-ylethyl)sulfonyl]phenyl}-5-phenyl-1,3-oxazol-2-amine;

3-{[5-(4-fluorophenyl)-1,3-oxazol-2-yl]amino}-4-methoxybenzenesulfonamide;

N-{5-[(1-ethylpropyl)sulfonyl]-2-methoxyphenyl}-5-(4-fluorophenyl)-1,3-oxazol-2-amine;

5-(4-fluorophenyl)-*N*-(2-methoxy-5-{[(5-methylisoxazol-3-yl)methyl]sulfonyl}phenyl)-1,3-oxazol-2-amine;

3-{[5-(3-bromophenyl)-1,3-oxazol-2-yl]amino}-4-methoxybenzenesulfonamide;

5-(4-fluorophenyl)-*N*-[5-(isobutylsulfonyl)-2-methoxyphenyl]-1,3-oxazol-2-amine;

5-(4-fluorophenyl)-*N*-{2-methoxy-5-[(tetrahydrofuran-2-ylmethyl)sulfonyl]phenyl}-1,3-oxazol-2-amine;

5-(4-fluorophenyl)-*N*-[2-methoxy-5-(tetrahydrofuran-3-ylsulfonyl)phenyl]-1,3-oxazol-2-amine;

5-(4-fluorophenyl)-*N*-(2-methoxy-5-{[2-(4-methyl-1,3-thiazol-5-yl)ethyl]sulfonyl}phenyl)-1,3-oxazol-2-amine;

5-(4-fluorophenyl)-*N*-[5-(isopropylsulfonyl)-2-methoxyphenyl]-1,3-oxazol-2-amine;

5-(3-bromophenyl)-*N*-[5-(isopropylsulfonyl)-2-methoxyphenyl]-1,3-oxazol-2-amine;

5-(4-fluorophenyl)-*N*-(5-{[2-(1*H*-imidazol-1-yl)ethyl]sulfonyl}-2-methoxyphenyl)-1,3-oxazol-2-amine;

5-(3-bromophenyl)-*N*-(2-methoxy-5-{[2-(4-methyl-1,3-thiazol-5-yl)ethyl]sulfonyl}phenyl)-1,3-oxazol-2-amine;

N-(2-ethoxyphenyl)-5-(3-methoxyphenyl)-1,3-oxazol-2-amine;

N-(3,4-dimethoxyphenyl)-5-(3-methoxyphenyl)-1,3-oxazol-2-amine;

N-(3,4-dimethoxyphenyl)-5-(4-fluorophenyl)-1,3-oxazol-2-amine;

N-(3,4-dimethoxyphenyl)-5-(4-methylphenyl)-1,3-oxazol-2-amine;

5-(3,4-dichlorophenyl)-*N*-(3,4-dimethoxyphenyl)-1,3-oxazol-2-amine;

5-[4-(diethylamino)phenyl]-*N*-(3,4-dimethoxyphenyl)-1,3-oxazol-2-amine;

5-(4-chloro-3-methylphenyl)-*N*-(3,4-dimethoxyphenyl)-1,3-oxazol-2-amine;

N-[5-(ethylsulfonyl)-2-methoxyphenyl]-5-(4-fluorophenyl)-1,3-oxazol-2-amine;

5-(3,4-difluorophenyl)-*N*-[5-(ethylsulfonyl)-2-methoxyphenyl]-1,3-oxazol-2-amine;

4-chloro-3-{[5-(4-fluorophenyl)-1,3-oxazol-2-yl]amino}-*N*,*N*-dimethylbenzenesulfonamide;

4-chloro-*N*,*N*-diethyl-3-{[5-(4-fluorophenyl)-1,3-oxazol-2-yl]amino}benzenesulfonamide;

5-(4-fluorophenyl)-*N*-[3-(methylsulfonyl)phenyl]-1,3-oxazol-2-amine;

N-[2-chloro-5-(methylsulfonyl)phenyl]-5-(4-fluorophenyl)-1,3-oxazol-2-amine;

N-[2-chloro-5-(ethylsulfonyl)phenyl]-5-(4-fluorophenyl)-1,3-oxazol-2-amine;

5-(4-fluorophenyl)-*N*-(3,4,5-trimethoxyphenyl)-1,3-oxazol-2-amine;

5-(3-bromophenyl)-*N*-(3,4,5-trimethoxyphenyl)-1,3-oxazol-2-amine;

5-(1,1'-biphenyl-3-yl)-*N*-(3,4,5-trimethoxyphenyl)-1,3-oxazol-2-amine;

4-methoxy-*N*-(2-morpholin-4-ylethyl)-3-[(5-phenyl-1,3-oxazol-2-yl)amino]benzenesulfonamide;

3-{[5-(4-fluorophenyl)-1,3-oxazol-2-yl]amino}-4-methoxy-*N*-(3-pyrrolidin-1-ylpropyl)benzenesulfonamide;

3-{[5-(4-fluorophenyl)-1,3-oxazol-2-yl]amino}-*N*-[3-(1*H*-imidazol-1-yl)propyl]-4-methoxybenzenesulfonamide;

3-{[5-(4-fluorophenyl)-1,3-oxazol-2-yl]amino}-4-methoxy-*N*-(pyridin-3-ylmethyl)benzenesulfonamide;

3-{[5-(4-fluorophenyl)-1,3-oxazol-2-yl]amino}-4-methoxy-*N*-(pyridin-4-ylmethyl)benzenesulfonamide;

3-{[5-(4-fluorophenyl)-1,3-oxazol-2-yl]amino}-*N*-isopropyl-4-methoxybenzenesulfonamide;

3-{[5-(4-fluorophenyl)-1,3-oxazol-2-yl]amino}-4-methoxy-*N*-(tetrahydrofuran-2-ylmethyl)benzenesulfonamide;

5-(4-fluorophenyl)-*N*-[2-methoxy-5-(morpholin-4-ylsulfonyl)phenyl]-1,3-oxazol-2-amine;

5-(4-fluorophenyl)-*N*-{2-methoxy-5-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}-1,3-oxazol-2-amine;

5-(4-fluorophenyl)-*N*-[2-methoxy-5-(thiomorpholin-4-ylsulfonyl)phenyl]-1,3-oxazol-2-amine;

N-(cyclopropylmethyl)-3-{[5-(4-fluorophenyl)-1,3-oxazol-2-yl]amino}-4-methoxybenzenesulfonamide;

3-{[5-(4-fluorophenyl)-1,3-oxazol-2-yl]amino}-4-methoxy-*N*-(3-methoxypropyl)benzenesulfonamide;

3-{[5-(4-fluorophenyl)-1,3-oxazol-2-yl]amino}-4-methoxy-*N*-methylbenzenesulfonamide;

N-(2-ethoxyethyl)-3-{[5-(4-fluorophenyl)-1,3-oxazol-2-yl]amino}-4-methoxybenzenesulfonamide;

N-[5-(isopropylsulfonyl)-2-methoxyphenyl]-5-(3-pyridin-2-ylphenyl)-1,3-oxazol-2-amine;

N-[2-methoxy-5-(tetrahydrofuran-3-ylsulfonyl)phenyl]-5-(3-pyridin-2-ylphenyl)-1,3-oxazol-2-amine;

N-[5-(isobutylsulfonyl)-2-methoxyphenyl]-5-(3-pyridin-2-ylphenyl)-1,3-oxazol-2-amine;

5-(1,1'-biphenyl-3-yl)-*N*-{2-methoxy-5-[(1-pyridin-4-ylethyl)sulfonyl]phenyl}-1,3-oxazol-2-amine;

N-{2-methoxy-5-[(tetrahydrofuran-2-ylmethyl)sulfonyl]phenyl}-5-(3-pyridin-2-ylphenyl)-1,3-oxazol-2-amine;

N-(2-methoxy-5-{[2-(4-methyl-1,3-thiazol-5-yl)ethyl]sulfonyl}phenyl)-5-(3-pyridin-2-ylphenyl)-1,3-oxazol-2-amine;

5-(4-chlorophenyl)-*N*-[5-(ethylsulfonyl)-2-methoxyphenyl]-1,3-oxazol-2-amine;

4-(2-{[5-(ethylsulfonyl)-2-methoxyphenyl]amino}-1,3-oxazol-5-yl)benzonitrile;

4-(2-{[5-(ethylsulfonyl)-2-methoxyphenyl]amino}-1,3-oxazol-5-yl)benzamide;

5-(4-bromophenyl)-*N*-[5-(ethylsulfonyl)-2-methoxyphenyl]-1,3-oxazol-2-amine;

N-[5-(ethylsulfonyl)-2-methoxyphenyl]-5-(3-methyl-1-benzothien-2-yl)-1,3-oxazol-2-amine;

5-(3-bromophenyl)-*N*-[5-(ethylsulfonyl)-2-methoxyphenyl]-1,3-oxazol-2-amine;

5-(3-chlorophenyl)-*N*-[5-(ethylsulfonyl)-2-methoxyphenyl]-1,3-oxazol-2-amine;

N-[5-(ethylsulfonyl)-2-methoxyphenyl]-5-pyridin-3-yl-1,3-oxazol-2-amine;

3-(2-{[5-(ethylsulfonyl)-2-methoxyphenyl]amino}-1,3-oxazol-5-yl)benzonitrile;

3-(2-{[5-(ethylsulfonyl)-2-methoxyphenyl]amino}-1,3-oxazol-5-yl)benzamide;

N-[5-(ethylsulfonyl)-2-methoxyphenyl]-5-(3-fluorophenyl)-1,3-oxazol-2-amine;

N-[5-(ethylsulfonyl)-2-methoxyphenyl]-5-[4-(trifluoromethyl)phenyl]-1,3-oxazol-2-amine;

5-(3,4-dichlorophenyl)-*N*-[5-(ethylsulfonyl)-2-methoxyphenyl]-1,3-oxazol-2-amine;

5-(4-chloro-3-methylphenyl)-*N*-[5-(ethylsulfonyl)-2-methoxyphenyl]-1,3-oxazol-2-amine;

5-[5-(2,4-dichlorophenyl)-2-furyl]-*N*-[5-(ethylsulfonyl)-2-methoxyphenyl]-1,3-oxazol-2-amine;

N-[5-(ethylsulfonyl)-2-methoxyphenyl]-5-(2-naphthyl)-1,3-oxazol-2-amine;

N-[5-(ethylsulfonyl)-2-methoxyphenyl]-5-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)-1,3-oxazol-2-amine;

5-(2,3-dihydro-1,4-benzodioxin-6-yl)-*N*-[5-(ethylsulfonyl)-2-methoxyphenyl]-1,3-oxazol-2-amine;

5-(3,5-difluorophenyl)-*N*-[5-(ethylsulfonyl)-2-methoxyphenyl]-1,3-oxazol-2-amine;

N-[5-(ethylsulfonyl)-2-methoxyphenyl]-5-(3-trifluoromethylphenyl)-1,3-oxazol-2-amine;

N-[5-(ethylsulfonyl)-2-methoxyphenyl]-5-[4-(methylsulfonyl)phenyl]-1,3-oxazol-2-amine;

5-(3,4-dimethoxyphenyl)-*N*-[5-(ethylsulfonyl)-2-methoxyphenyl]-1,3-oxazol-2-amine;

5-(3,4-dihydro-2*H*-1,5-benzodioxepin-7-yl)-*N*-[5-(ethylsulfonyl)-2-methoxyphenyl]-1,3-oxazol-2-amine;

5-(5-chlorothien-2-yl)-*N*-[5-(ethylsulfonyl)-2-methoxyphenyl]-1,3-oxazol-2-amine;

methyl 3-{[5-(3-bromophenyl)-1,3-oxazol-2-yl]amino}-4-methoxybenzoate;

3-{[5-(3-bromophenyl)-1,3-oxazol-2-yl]amino}-4-methoxybenzenesulfonyl fluoride;

3-(2-{[5-(ethylsulfonyl)-2-methoxyphenyl]amino}-1,3-oxazol-5-yl)phenyl benzoate;

3-(2-{[5-(ethylsulfonyl)-2-methylphenyl]amino}-1,3-oxazol-5-yl)phenol;

5-[3-(cyclopropylmethoxy)phenyl]-*N*-[5-(ethylsulfonyl)-2-methoxyphenyl]-1,3-oxazol-2-amine;

5-(3-butoxyphenyl)-*N*-[5-(ethylsulfonyl)-2-methoxyphenyl]-1,3-oxazol-2-amine;

N-[5-(ethylsulfonyl)-2-methoxyphenyl]-5-[3-(pyridin-2-ylmethoxy)phenyl]-1,3-oxazol-2-amine;

5-(3-benzyloxyphenyl)-*N*-[5-(ethylsulfonyl)-2-methoxyphenyl]-1,3-oxazol-2-amine;

N-[5-(ethylsulfonyl)-2-methoxyphenyl]-5-[3-(tetrahydro-2*H*-pyran-4-yloxy)phenyl]-1,3-oxazol-2-amine;

N-[5-(ethylsulfonyl)-2-methoxyphenyl]-5-[3-(2-pyridin-2-ylethoxy)phenyl]-1,3-oxazol-2-amine;

5-{3-[(2,3-dimethoxybenzyl)oxy]phenyl}-*N*-[5-(ethylsulfonyl)-2-methoxyphenyl]-1,3-oxazol-2-amine;

N-[5-(ethylsulfonyl)-2-methoxyphenyl]-5-[3-(1-pyridin-4-ylethoxy)phenyl]-1,3-oxazol-2-amine;

N-[5-(ethylsulfonyl)-2-methoxyphenyl]-5-[3-(tetrahydrofuran-3-yloxy)phenyl]-1,3-oxazol-2-amine;

5-{3-[(2-chloropyrimidin-4-yl)oxy]phenyl}-*N*-[5-(ethylsulfonyl)-2-methoxyphenyl]-1,3-oxazol-2-amine;

4-[3-(2-{[5-(ethylsulfonyl)-2-methoxyphenyl]amino}-1,3-oxazol-5-yl)phenoxy]-*N*-isopropylpyrimidin-2-amine;

N-[5-(ethylsulfonyl)-2-methoxyphenyl]-5-(3-phenoxyphenyl)-1,3-oxazol-2-amine;

5-(3',5'-difluoro-1,1'-biphenyl-3-yl)-*N*-[5-(ethylsulfonyl)-2-methoxyphenyl]-1,3-oxazol-2-amine;

N-[5-(ethylsulfonyl)-2-methoxyphenyl]-5-(3-thien-2-ylphenyl)-1,3-oxazol-2-amine;

N-[5-(ethylsulfonyl)-2-methoxyphenyl]-5-(3-thien-3-ylphenyl)-1,3-oxazol-2-amine;

N-[5-(ethylsulfonyl)-2-methoxyphenyl]-5-(3-pyridin-3-ylphenyl)-1,3-oxazol-2-amine;

N-[5-(ethylsulfonyl)-2-methoxyphenyl]-5-(3-vinylphenyl)-1,3-oxazol-2-amine;

5-(3-ethylphenyl)-*N*-[5-(ethylsulfonyl)-2-methoxyphenyl]-1,3-oxazol-2-amine;

N-[5-(ethylsulfonyl)-2-methoxyphenyl]-5-(3-pyridin-4-ylphenyl)-1,3-oxazol-2-amine;

N-[5-(ethylsulfonyl)-2-methoxyphenyl]-5-(3-pyridin-2-ylphenyl)-1,3-oxazol-2-amine;

N-[5-(ethylsulfonyl)-2-methoxyphenyl]-5-[3-(1-methyl-1*H*-imidazol-5-yl)phenyl]-1,3-oxazol-2-amine;

5-(1,1'-biphenyl-3-yl)-*N*-[5-(ethylsulfonyl)-2-methoxyphenyl]-1,3-oxazol-2-amine;

N-[5-(ethylsulfonyl)-2-methoxyphenyl]-5-[3-(2-furyl)phenyl]-1,3-oxazol-2-amine;

N-[5-(ethylsulfonyl)-2-methoxyphenyl]-5-(3-pyrazin-2-ylphenyl)-1,3-oxazol-2-amine;

N-[5-(ethylsulfonyl)-2-methoxyphenyl]-5-(4'-fluoro-1,1'-biphenyl-3-yl)-1,3-oxazol-2-amine;

5-[3-(2,3-dihydro-1-benzofuran-5-yl)phenyl]-*N*-[5-(ethylsulfonyl)-2-methoxyphenyl]-1,3-oxazol-2-amine;

N-[5-(ethylsulfonyl)-2-methoxyphenyl]-5-[3-(1,3-thiazol-2-yl)phenyl]-1,3-oxazol-2-amine;

4-methoxy-3-{[5-(3-pyridin-3-ylphenyl)-1,3-oxazol-2-yl]amino}benzenesulfonamide;

3-{[5-(1,1'-biphenyl-3-yl)-1,3-oxazol-2-yl]amino}-4-methoxybenzenesulfonamide;

4-methoxy-3-({5-[3-(1-methyl-1*H*-imidazol-5-yl)phenyl]-1,3-oxazol-2-yl}amino)benzenesulfonamide;

3-{[5-(4'-fluoro-1,1'-biphenyl-3-yl)-1,3-oxazol-2-yl]amino}-4-methoxy-*N*-methylbenzenesulfonamide;

methyl 4-methoxy-3-{[5-(3-pyridin-2-ylphenyl)-1,3-oxazol-2-yl]amino}benzoate;

3-{[5-(4'-fluoro-1,1'-biphenyl-3-yl)-1,3-oxazol-2-yl]amino}-4-methoxybenzenesulfonamide;

N-{5-[(1-ethylpropyl)sulfonyl]-2-methoxyphenyl}-5-(3-pyridin-2-ylphenyl)-1,3-oxazol-2-amine;

1-[3-(2-{[5-(ethylsulfonyl)-2-methoxyphenyl]amino}-1,3-oxazol-5-yl)phenyl]ethanone;

1-[4-(2-{[5-(ethylsulfonyl)-2-methoxyphenyl]amino}-1,3-oxazol-5-yl)phenyl]ethanone;

4-methoxy-3-{[5-(3-pyridin-3-ylphenyl)-1,3-oxazol-2-yl]amino}benzenesulfonyl fluoride;

4-methoxy-3-{[5-(3-pyridin-2-ylphenyl)-1,3-oxazol-2-yl]amino}benzenesulfonyl fluoride;

3'-(2-{[5-(ethylsulfonyl)-2-methoxyphenyl]amino}-1,3-oxazol-5-yl)-1,1'-biphenyl-4-carbonitrile;

3'-(2-{[5-(ethylsulfonyl)-2-methoxyphenyl]amino}-1,3-oxazol-5-yl)-1,1'-biphenyl-3-carboxylic acid;

3'-(2-{[5-(ethylsulfonyl)-2-methoxyphenyl]amino}-1,3-oxazol-5-yl)-1,1'-biphenyl-3-carbonitrile;

N-[5-(ethylsulfonyl)-2-methoxyphenyl]-5-(3'-fluoro-1,1'-biphenyl-3-yl)-1,3-oxazol-2-amine;

N-[5-(ethylsulfonyl)-2-methoxyphenyl]-5-(3-quinolin-3-ylphenyl)-1,3-oxazol-2-amine;

N-[5-(ethylsulfonyl)-2-methoxyphenyl]-5-[3-(5-methylthien-2-yl)phenyl]-1,3-oxazol-2-amine;

N-[5-(ethylsulfonyl)-2-methoxyphenyl]-5-[3-(1*H*-indol-5-yl)phenyl]-1,3-oxazol-2-amine;

methyl 3'-(2-{[5-(ethylsulfonyl)-2-methoxyphenyl]amino}-1,3-oxazol-5-yl)-1,1'-biphenyl-4-carboxylate;

3-{[5-(3'-fluoro-1,1'-biphenyl-3-yl)-1,3-oxazol-2-yl]amino}-4-methoxy-*N*-methylbenzenesulfonamide;

3-{[5-(1,1'-biphenyl-3-yl)-1,3-oxazol-2-yl]amino}-4-methoxybenzenesulfonyl fluoride;

3-{[5-(3'-fluoro-1,1'-biphenyl-3-yl)-1,3-oxazol-2-yl]amino}-4-methoxybenzenesulfonamide;

N-[5-(ethylsulfonyl)-2-methoxyphenyl]-5-(2'-fluoro-1,1'-biphenyl-3-yl)-1,3-oxazol-2-amine;

5-(2'-chloro-1,1'-biphenyl-3-yl)-*N*-[5-(ethylsulfonyl)-2-methoxyphenyl]-1,3-oxazol-2-amine;

4-methoxy-*N*-methyl-3-{[5-(3-pyridin-2-ylphenyl)-1,3-oxazol-2-yl]amino}benzenesulfonamide;

N-ethyl-4-methoxy-3-{[5-(3-pyridin-2-ylphenyl)-1,3-oxazol-2-yl]amino}benzenesulfonamide;

4-methoxy-3-{[5-(3-pyridin-2-ylphenyl)-1,3-oxazol-2-yl]amino}benzenesulfonamide;

N-isopropyl-4-methoxy-3-{[5-(3-pyridin-2-ylphenyl)-1,3-oxazol-2-yl]amino}benzenesulfonamide;

N-(cyclopropylmethyl)-4-methoxy-3-{[5-(3-pyridin-2-ylphenyl)-1,3-oxazol-2-yl]amino}benzenesulfonamide;

N,N-diethyl-4-methoxy-3-{[5-(3-pyridin-2-ylphenyl)-1,3-oxazol-2-yl]amino}benzenesulfonamide;

N-isopropyl-4-methoxy-3-{[5-(3-pyridin-3-ylphenyl)-1,3-oxazol-2-yl]amino}benzenesulfonamide;

3-{[5-(1,1'-biphenyl-3-yl)-1,3-oxazol-2-yl]amino}-*N*-isopropyl-4-methoxybenzenesulfonamide;

3-{[5-(1,1'-biphenyl-3-yl)-1,3-oxazol-2-yl]amino}-4-methoxy-*N,N*-dimethylbenzenesulfonamide;

3-{[5-(1,1'-biphenyl-3-yl)-1,3-oxazol-2-yl]amino}-*N*-cyclopropyl-4-methoxybenzenesulfonamide;

3-{[5-(1,1'-biphenyl-3-yl)-1,3-oxazol-2-yl]amino}-*N*-butyl-4-methoxybenzenesulfonamide;

3-{[5-(1,1'-biphenyl-3-yl)-1,3-oxazol-2-yl]amino}-*N,N*-diethyl-4-methoxybenzenesulfonamide;

3-{[5-(1,1'-biphenyl-3-yl)-1,3-oxazol-2-yl]amino}-4-methoxy-*N*-(tetrahydrofuran-2-ylmethyl)benzenesulfonamide;

4-[3-(2-{[5-(ethylsulfonyl)-2-methoxyphenyl]amino}-1,3-oxazol-5-yl)phenyl]-*N*-isopropylpyrimidin-2-amine;

N-benzyl-4-[3-(2-{[5-(ethylsulfonyl)-2-methoxyphenyl]amino}-1,3-oxazol-5-yl)phenyl]pyrimidin-2-amine;

N^1-{4-[3-(2-{[5-(ethylsulfonyl)-2-methoxyphenyl]amino}-1,3-oxazol-5-yl)phenyl]pyrimidin-2-yl}-N^3,N^3-dimethylpropane-1,3-diamine;

N-[5-(ethylsulfonyl)-2-methoxyphenyl]-5-[3-(2-phenylpyrimidin-4-yl)phenyl]-1,3-oxazol-2-amine;

N-[5-(ethylsulfonyl)-2-methoxyphenyl]-5-[3-(2-isopropylpyrimidin-4-yl)phenyl]-1,3-oxazol-2-amine;

5-[3-(2-*tert*-butylpyrimidin-4-yl)phenyl]-*N*-[5-(ethylsulfonyl)-2-methoxyphenyl]-1,3-oxazol-2-amine;

3'-(2-{[5-(ethylsulfonyl)-2-methoxyphenyl]amino}-1,3-oxazol-5-yl)-1,1'-biphenyl-4-carboxylic acid;

3'-(2-{[5-(ethylsulfonyl)-2-methoxyphenyl]amino}-1,3-oxazol-5-yl)-*N*-(2-morpholin-4-ylethyl)-1,1'-biphenyl-4-carboxamide; and

3'-(2-{[5-(ethylsulfonyl)-2-methoxyphenyl]amino}-1,3-oxazol-5-yl)-*N*-[3-(4-methylpiperazin-1-yl)propyl]-1,1'-biphenyl-4-carboxamide;

or a salt, solvate, or physiologically functional derivative thereof.

6. (Currently amended) A pharmaceutical composition, comprising: a therapeutically effective amount of a compound as claimed in ~~any one of~~ claims 1 ~~to 5~~, or a salt, solvate, or a physiologically functional derivative thereof and one or more of pharmaceutically acceptable carriers, diluents and excipients.

7. (Original) The pharmaceutical composition of claim 6, further comprising at least one additional anti-neoplastic agent.

8. (Original) The pharmaceutical composition of claim 7, further comprising an additional agent which inhibits angiogenesis.

9. (Currently amended) A method of treating a disorder in a mammal, said disorder being mediated by inappropriate VEGFR2, CDK2, and/or CDK4

activity, comprising: administering to said mammal a therapeutically effective amount of a compound as claimed in ~~any one of~~ claim~~s~~ 1 ~~to 5~~, or a salt, solvate, or a physiologically functional derivative thereof.

10. (Original) The method of claim 9, wherein the disorder is cancer.

11. (Currently amended) A method of treating a disorder in a mammal, said disorder being mediated by inappropriate VEGFR2 activity, comprising: administering to said mammal a therapeutically effective amount of a compound as claimed in ~~any one of~~ claim~~s~~ 1 ~~to 5~~, or a salt, solvate, or a physiologically functional derivative thereof.

12. (Original) The method of claim 11, wherein the disorder is cancer.

13. (Currently amended) A method of treating a disorder in a mammal, said disorder being mediated by inappropriate CDK2 and/or CDK4 activity, comprising: administering to said mammal a therapeutically effective amount of a compound as claimed in ~~any one of~~ claim~~s~~ 1 ~~to 5~~, or a salt, solvate, or a physiologically functional derivative thereof.

14. (Original) The method of claim 13, wherein the disorder is cancer.

Claims 15-21 (Cancelled)

22. (Currently amended) A method of treating cancer in a mammal, comprising: administering to said mammal a therapeutically effective amount of a compound as claimed in ~~any one of~~ claim~~s~~ 1 ~~to 5~~, or a salt, solvate, or a physiologically functional derivative thereof.

23. (Original) The method of claim 22, further comprising administering a therapeutically effective amount of at least one additional anti-cancer therapy.

24. (Currently amended) The method of claim 23, wherein the additional anti-cancer therapy is administered concomitantly with the administration of the compound, salt, solvate or physiologically functional derivative as claimed in ~~any one of~~ claim~~s~~ 1 ~~to 5~~.

25. (Currently amended) The method of claim 23, wherein the additional anti-cancer therapy is administered after the administration of the compound, salt, solvate or physiologically functional derivative as claimed in ~~any one of~~ claim~~s~~ 1 ~~to 5~~.

26. (Currently amended) The method of claim 25, wherein the additional anti-cancer therapy is administered before the administration of the compound, salt, solvate or physiologically functional derivative as claimed in ~~any one of~~ claim~~s~~ 1 ~~to 5~~.

27. (Currently amended) A method of treating a disorder in a mammal, said disorder being mediated by inappropriate VEGFR2 activity, comprising: administering to said mammal therapeutically effective amounts of (1) a compound as claimed in ~~any one of~~ claim~~s~~ 1 ~~to 5~~, or a salt, solvate or physiologically functional derivative thereof and (ii) an agent to inhibit growth factor receptor function.

28. (Original) The method of claim 27, wherein the agent to inhibit growth factor receptor function inhibits the function of platelet derived growth factor receptor.

29. (Original) The method of claim 27, wherein the agent to inhibit growth factor receptor function inhibits the function of epidermal growth factor receptor.

30. (Original) The method of claim 27, wherein the agent to inhibit growth factor receptor function inhibits the function of the erbB2 receptor.

31. (Original) The method of claim 27, wherein the agent to inhibit growth factor receptor function inhibits the function of a VEGF receptor.

32. (Original) The method of claim 27, wherein the agent to inhibit growth factor receptor function inhibits the function of the TIE-2 receptor.

33. (Original) The method of claim 27, wherein the agent to inhibit growth factor receptor function inhibits the function of the epidermal growth factor receptor and erbB2.

34. (Original) The method of claim 27, wherein the agent to inhibit growth factor receptor function inhibits the function of at least two of the epidermal growth factor receptor, erbB2, and erbB4.

35. (Original) The method of claim 27, wherein the agent to inhibit growth factor receptor function inhibits the function of the VEGF receptor and the TIE-2 receptor.

36. (Original) The method of claim 27, wherein the disorder is cancer.

37. (Currently amended) A method of treating a disorder in a mammal, said disorder being characterized by inappropriate angiogenesis, comprising: administering to said mammal a therapeutically effective amount of a compound as claimed in ~~any one of~~ claim~~s~~ 1 ~~to 5~~, or a salt, solvate or physiologically functional derivative thereof.

38. (Original) The method of claim 37, wherein the inappropriate angiogenesis results from at least one of inappropriate VEGFR1, VEGFR2, VEGFR3 or TIE-2 activity.

39. (Original) The method of claim 37, wherein the inappropriate angiogenesis results from inappropriate VEGFR2 and TIE-2 activity.

40. (Original) The method of claim 37, further comprising administering a therapeutically effective amount of a TIE-2 inhibitor.

41. (Original) The method of claim 37, further comprising administering an agent to inhibit growth factor receptor function.

42. (Original) The method of claim 37, wherein the disorder is cancer.

43. (Cancelled)

44. (Currently amended) A method of treating a disorder in a mammal, said disorder being mediated by inappropriate CDK2 and/or CDK4 activity, comprising: administering to said mammal therapeutically effective amounts of (1) a compound as claimed in ~~any one of~~ claim~~s~~ 1 ~~to 5~~, or a salt, solvate or physiologically functional derivative thereof and (ii) an agent to inhibit growth factor receptor function.